Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 20.34 +0.15 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.19 | 52 Week High | $42.49 | |||
| Open | $20.30 | 52 Week Low | $16.64 | |||
| Day High | $20.50 | P/E | N/A | |||
| Day Low | $20.21 | EPS | $-0.42 | |||
| Volume | 104,059 | |||||
